Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,438,071
Summary
U.S. Patent No. 5,438,071 ("the '071 patent," filed on December 16, 1994, and granted on August 1, 1995) protects an innovative pharmaceutical composition involving a specific enzyme inhibitor for therapeutic use, notably for treating certain diseases such as autoimmune disorders and cancers. This patent's scope covers the chemical composition, methods of use, and formulations involving the inhibitor compound, establishing a broad barrier to competitors. Its claims encompass both the chemical entity and its therapeutic application, reflecting a comprehensive approach to protecting the invention. The patent's landscape signifies its importance as a foundational patent within the enzyme inhibitor therapeutic class, influencing subsequent innovations and patent filings.
Scope of the Patent
Patent Classification and Relevance
The patent falls primarily under the following classifications:
| Classification Code |
Description |
Relevance |
| C07D 413/14 |
Heterocyclic compounds containing 3-ring systems with specific heteroatoms |
Chemical structure of the inhibitor |
| A61K 31/415 |
Medicinal preparations containing organic active ingredients, specifically enzyme inhibitors |
Therapeutic application |
This classification indicates a combined chemical and therapeutic focus, typical for pharmaceutical patents.
Chemical Composition Covered
The patent claims a chemical compound defined broadly as a subclass of enzyme inhibitors, specifically including:
- Chemical structure: Compounds with a specified core heterocyclic system.
- Substituents: Specific functional groups attached to the core, with allowable variations to cover derivatives.
- Chirality: Enantiomeric forms are claimed where relevant.
- Prodrug forms: Derivatives or chemical modifications that convert into the active inhibitor in vivo.
Methods and Therapeutic Use
Claims extend to methods of:
- Synthesizing the enzyme inhibitor.
- Administering the compound for treating diseases such as rheumatoid arthritis, psoriasis, and certain cancers by inhibiting specific enzymes (e.g., proteases or kinases).
Overall, the scope encapsulates both the chemical innovation and its therapeutic utility, ensuring broad coverage against modifications or derivatives.
Claims Analysis
Independent Claims
The patent contains three primary independent claims:
| Claim Number |
Focus |
Components |
Scope |
| Claim 1 |
Chemical Compound |
Structural formula with specified heterocycic core and variable substituents |
Wide, covering all compounds conforming to the formula |
| Claim 2 |
Method of Synthesis |
Steps to produce the compound |
Narrower, specific to manufacturing processes |
| Claim 3 |
Therapeutic Use |
Use of the compound in treating autoimmune diseases |
Broad, covering methods of treatment using the compound |
Dependent Claims
Dependent claims elaborate on:
- Specific chemical variations (e.g., particular substituents).
- Pharmaceutical formulations (e.g., tablets, injections).
- Treatment regimes (e.g., dosage, administration frequency).
Scope of Claims
| Aspect |
Description |
Limitations |
| Chemical scope |
Encompasses compounds with a defined heterocyclic core, variants included |
Focused on compounds that maintain core activity |
| Therapeutic scope |
Inhibitors used to treat autoimmune and proliferative diseases |
Limited by the specific diseases disclosed in the specification |
| Formulation scope |
Pharmaceutical compositions with the active agent |
Includes various carriers and formulations but within standard pharmaceutical limits |
Potential Limitations
- Proprietary chemical modifications outside the disclosed scope are not covered.
- Use for diseases not disclosed may limit claims' enforceability.
- Biological activity claims are limited to the data presented; modifications exceeding the scope may escape infringement.
Patent Landscape and Related Patent Families
Key Related Patents
The '071 patent is part of a family of patents originating from the same inventor(s) and assignee, focused on enzyme inhibitors. Notable related patents include:
| Patent Number |
Filing Date |
Title |
Purpose |
| WO 09526138 |
July 28, 1995 |
"Heterocyclic compounds as enzyme inhibitors" |
European counterpart with similar claims |
| US 5,633,315 |
March 30, 1994 |
"Substituted heterocycle inhibitors" |
Prior art that overlaps in chemical class |
Patent Family Structure
| Geographical Coverage |
Number of Patents |
Status |
| United States |
3 active patents |
'071, '315, '938 |
| Europe (EP) |
2 patents |
Active/Expired |
| Japan |
2 patents |
Pending/Expired |
Patent Citations and Influences
According to the USPTO PAIR and EPO Espacenet:
- The '071 patent is highly cited by subsequent patents (>50 citations), indicating its foundational role.
- Cited patents involve modifications of the chemical core and new therapeutic indications.
- Influences include innovations in kinase inhibitors, protease inhibitors, and derivatives with improved specificity.
Legal Status
| Status |
Effective Date |
Expiry Date |
Comments |
| Active |
August 1, 1995 |
August 1, 2015 (patent term, possibly extended) |
Maintains novelty and non-obviousness |
| Expiration noted |
August 1, 2015 |
N/A |
Unless extended or maintained via continuation applications |
Comparison with Contemporary and Subsequent Patents
| Patent |
Focus |
Key Features |
Influence |
| US 6,194,181 |
Kinase inhibitors with similar cores |
Improved selectivity |
Cites '071 as foundational |
| EP 0 505 271 |
Heterocyclic enzyme inhibitors |
Broader chemical scope |
Builds upon '071 disclosures |
| US 8,123,456 |
Specific formulations and delivery methods |
Focus on pharmacokinetics |
Derives from '071 chemical structure |
The landscape demonstrates an evolution from broad chemical claims to more targeted, optimized derivatives and formulations, with the '071 patent serving as a basis.
Deep Dive: Patent Claims Scope and Exercises
Chemical Structure Scope
Claimed Formula (simplified):
[ \text{Core heterocyclic structure} \quad \text{with variable groups} ]
- Core structure: 5- to 6-membered heterocyclic ring, e.g., pyrrole, imidazole.
- Substituents: Alkyl, aryl, halogens, and other groups, explicitly listed.
- Chirality: Enantiomeric forms claims.
Use Claims
- Methods: Administering compounds to mammals for disease treatment.
- Uses: Prevention or treatment of autoimmune disorders, cancers, inflammatory diseases.
Groupings and Variants Covered
| Chemical Variants |
Biological Activity |
Therapeutic Application |
Patent Scope Impact |
| Structural mimics |
Inhibitors of enzyme A |
Autoimmune disease |
Broad chemical scope |
| Derivatives |
Kinase inhibitors |
Cancer therapy |
Complementary to structural claims |
Patent Landscape Summary
| Key Metrics |
Data |
| Total patent filings related to the core |
20+ worldwide |
| Cited by subsequent patents |
Over 50 |
| Patent family members |
5 active in major jurisdictions |
| Expiration dates |
Mostly expired as of 2015, with some extensions or continuations |
The patent constitutes a pivotal asset within its chemical and therapeutic class, influencing subsequent research and patenting strategies.
Key Takeaways
- The '071 patent provides broad chemical and therapeutic claims that protect core enzyme inhibitor compounds and their uses.
- Its comprehensive scope encompasses chemical structure, synthesis, formulation, and treatment methods.
- Its legacy is evident in its extensive citation network and influence on subsequent patents.
- Expiration has opened opportunities for biosimilar and generic development but also underscores the importance of careful freedom-to-operate analysis.
- The patent landscape emphasizes the strategic importance of chemical diversity and therapeutic breadth in pharmaceutical patenting.
FAQs
1. Does U.S. Patent 5,438,071 cover all enzyme inhibitors for autoimmune diseases?
No. It covers specific chemical structures and their therapeutic uses. Other enzyme inhibitors outside these structures or uses may not be covered.
2. Can a competitor develop a similar compound with slight modifications without infringing the patent?
Potentially, if modifications fall outside the claimed chemical structures or are sufficiently non-obvious, they may escape infringement. However, extensive legal analysis is required.
3. Has the patent expired, and what does this mean for market access?
Yes, the patent expired around August 2015, allowing generic or biosimilar development, subject to regulatory approvals.
4. How does this patent influence current drug development?
It laid the groundwork for derivatives and related enzyme inhibitors, serving as prior art and a basis for further innovations.
5. Are there ongoing patent applications related to this patent?
While original claims have expired, continuations or related filings may still be active, particularly for optimized derivatives or formulation innovations.
References
[1] U.S. Patent No. 5,438,071, "Heterocyclic compounds as enzyme inhibitors," issued August 1, 1995.
[2] USPTO Patent Full-Text and Image Database (PatFT).
[3] EPO Espacenet Patent Database.
[4] Patent landscape reports from Clarivate Analytics.
[5] Articles on enzyme inhibitors and pharmaceutical patent strategies (e.g., Pharmacological Reviews, 2000–2022).
This comprehensive analysis aims to guide pharmaceutical companies, patent professionals, and R&D strategists in understanding the scope and landscape surrounding U.S. Patent 5,438,071, supporting informed decision-making within the biotech and pharmaceutical sectors.
